Chest
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weitz, J. I.
Right arrow Articles by Samama, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weitz, J. I.
Right arrow Articles by Samama, M. M.
(Chest. 2004;126:265S-286S.)
© 2004 American College of Chest Physicians

New Anticoagulant Drugs

The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Jeffrey I. Weitz, MD, FCCP; Jack Hirsh, MD, FCCP and Meyer M. Samama, MD

Correspondence to: Jeffrey Weitz, FCCP, 711 Concession St, Hamilton, ON, L8V 1C3 Canada; e-mail: jweitz{at}thrombosis.hhscr.org

This article about new anticoagulant drugs is part of the seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. The limitations of existing oral and parenteral anticoagulant agents have prompted a search for novel agents. Focusing on new anticoagulant drugs for the prevention and treatment of arterial and venous thrombosis, this article (1) reviews arterial and venous thrombogenesis, (2) discusses the regulation of coagulation, (3) describes the pathways for testing new anticoagulant agents, (4) describes new anticoagulant strategies focusing primarily on agents in phase II or III clinical testing, and (5) provides clinical perspective as to which of these new strategies is most likely to succeed.

Key Words: anticoagulants • antithrombotic drugs • profibrinolytic agents




This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
E. A Nutescu, A. K Wittkowsky, P. P Dobesh, D. W Hawkins, and W. E Dager
Choosing the Appropriate Antithrombotic Agent for the Prevention and Treatment of VTE: A Case-Based Approach
Ann. Pharmacother., September 1, 2006; 40(9): 1558 - 1570.
[Abstract] [Full Text] [PDF]

Home page
 CLIN APPL THROMB HEMOSTHome page
M. Adess, R. Eisner, S. Nand, J. Godwin, H. L. Messmore Jr, and W. H. Wehrmacher
Thromboembolism in Cancer Patients: Pathogenesis and Treatment
Clinical and Applied Thrombosis/Hemostasis, July 1, 2006; 12(3): 254 - 266.
[Abstract] [PDF]

Home page
 Eur Heart J SupplHome page
M. O'Donnell, G. Agnelli, and J. I. Weitz
Emerging therapies for stroke prevention in atrial fibrillation
Eur. Heart J. Suppl., May 1, 2005; 7(suppl_C): C19 - C27.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J. I. Weitz, S. Middeldorp, W. Geerts, and J. A. Heit
Thrombophilia and New Anticoagulant Drugs
Hematology, January 1, 2004; 2004(1): 424 - 438.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American College of Chest Physicians.